Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq:RIGL) granted equity awards under its Inducement Plan, approved by the board’s Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq:RIGL) granted equity awards under its Inducement Plan, approved by the board’s Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4).
The company granted 13,375 restricted stock units to six new non-executive employees, vesting over four years with 25% vesting each year.
Details
News Market Reaction – RIGL
On Jul 7, the day this news came out, RIGL closed 5.73% above the previous close. Argus tracked a peak move of +2.8% during that session. Our momentum scanner recorded 10 alerts for this stock that day. Relative volume reached 1.9x the daily average during tracking.
Data tracked by StockTitan Argus for the Jul 7 session.
Key Figures
- Restricted stock units
- 13,375 units
- Inducement grants to new employees under Inducement Plan
- Employees receiving awards
- 6 employees
- Non-executive hires granted inducement RSUs
- Vesting period
- 4 years
- RSU awards vest over four-year schedule
- Annual vesting rate
- 25% per year
- One-quarter of each RSU grant vests annually
Historical Context
-
Board member appointed Executive Vice President and Chief Medical Officer.
-
Closed global license for FDA-approved VEPPANU with $70M upfront payment.
-
CEO scheduled to present company overview at Jefferies healthcare conference.
-
Planned ASCO and EHA presentations on multiple oncology and hematology products.
-
CFO to deliver company overview at RBC Capital Markets healthcare conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302818799.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.